Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05021978




Registration number
NCT05021978
Ethics application status
Date submitted
20/08/2021
Date registered
26/08/2021
Date last updated
1/03/2024

Titles & IDs
Public title
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
Scientific title
A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults With Essential Tremor
Secondary ID [1] 0 0
PRAX-944-221
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Essential Tremor 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Part A: 20 and 40 mg PRAX-944
Treatment: Drugs - Part B: 120 mg PRAX-944
Treatment: Drugs - Part B: 120 mg PRAX-944 and Placebo

Experimental: Part A: Open-label 20 and 40 mg PRAX-944 - Once daily, oral dosing with 7 days of 20 mg and 7 days of 40 mg

Experimental: Part B: Open-label titration PRAX-944 (120 mg) followed by blinded PRAX-944 - Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg

Active comparator: Part B: Open-label titration PRAX-944 (120 mg) followed by blinded placebo - Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 14 days of 120 mg, 14 days placebo


Treatment: Drugs: Part A: 20 and 40 mg PRAX-944
Once daily oral treatment

Treatment: Drugs: Part B: 120 mg PRAX-944
Once daily oral treatment with titration

Treatment: Drugs: Part B: 120 mg PRAX-944 and Placebo
Once daily oral treatment with titration followed by placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score
Timepoint [1] 0 0
Baseline (Day 0), Days 7 and 14
Primary outcome [2] 0 0
Part B: Number of Participants With Adverse Events (AE), Related AE, and AE Leading to Treatment Discontinuation
Timepoint [2] 0 0
Up to Day 70
Primary outcome [3] 0 0
Part B: Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Values and Electrocardiogram Parameters
Timepoint [3] 0 0
Up to Day 70
Primary outcome [4] 0 0
Part B: Number of Participants With Suicidal Ideation or Behavior Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS)
Timepoint [4] 0 0
Up to Day 70
Secondary outcome [1] 0 0
Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale
Timepoint [1] 0 0
Baseline (Day 0), Days 7 and 14
Secondary outcome [2] 0 0
Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score Measured by Accelerometry
Timepoint [2] 0 0
Baseline (Day 0), Days 7 and 14
Secondary outcome [3] 0 0
Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Individual Items # 6 (Spiral Drawing) and Items #7 (Handwriting)
Timepoint [3] 0 0
Baseline (Day 0), Days 7 and 14
Secondary outcome [4] 0 0
Part A: Number of Participants With Adverse Events (AE), Related AE, and AE Leading to Treatment Discontinuation
Timepoint [4] 0 0
Up to Day 21
Secondary outcome [5] 0 0
Part A: Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Values and Electrocardiogram Parameters
Timepoint [5] 0 0
Up to Day 21
Secondary outcome [6] 0 0
Part A: Number of Participants With Suicidal Ideation or Behavior Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS)
Timepoint [6] 0 0
Up to Day 21
Secondary outcome [7] 0 0
Part B: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score During OLT Phase
Timepoint [7] 0 0
Baseline (Day 0) and Day 42
Secondary outcome [8] 0 0
Part B: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score During OLT Phase
Timepoint [8] 0 0
Baseline (Day 0), Days 7 and 21
Secondary outcome [9] 0 0
Part B: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale During OLT Phase
Timepoint [9] 0 0
Baseline (Day 0) and Days 7, 21 and 42
Secondary outcome [10] 0 0
Part B: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score Measured by Accelerometry During OLT Phase
Timepoint [10] 0 0
Baseline (Day 0), and Days 7, 21 and 42
Secondary outcome [11] 0 0
Part B: Change From Baseline in TETRAS Performance Subscale Individual Items # 6 (Spiral Drawing) and Items #7 (Handwriting)
Timepoint [11] 0 0
Baseline (Day 0), Days 7, 21 and 42
Secondary outcome [12] 0 0
Part B: Change From Baseline in TETRAS Activities of Daily Living (ADL) Score
Timepoint [12] 0 0
Baseline (Day 0), Days 7, 21 and 42
Secondary outcome [13] 0 0
Part B: Change From Baseline in Quality of Life in Essential Tremor Questionnaire (QUEST) Total Scores.
Timepoint [13] 0 0
Baseline (Day 0), Days 7, 21 and 42

Eligibility
Key inclusion criteria
1. Clinical diagnosis of ET consistent with Movement Disorders Society Criteria, a duration of ET of at least 3 years and with onset before the age of 65
2. TETRAS upper limb score (ie, sum of bilateral upper limb items 4a, 4b, and 4c) of =10 as rated by the Investigator at Screening and Baseline OR A score of =2 on 2 or more of the following TETRAS activities of daily living (ADL) subscale items: (2) Feeding with a spoon, (3) Drinking from a glass, (5) Dressing, (6) Pouring, (9) Writing OR A score of =2 on 1 of the following TETRAS ADL subscale items: (2) Feeding with a spoon, (3) Drinking from a glass, (5) Dressing, (6) Pouring, or (9) Writing AND a score of =2 on both of the following TETRAS ADL subscale items: (10) Working and (12) Social Impact
3. If currently receiving any medication for ET, is on a stable dose of any of these medications for ET for 28 days prior to Screening and is willing to maintain stable doses throughout the trial. If receiving primidone for ET, is willing and able to discontinue 14 days prior to Day 1.
4. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Sporadically using a benzodiazepine, sleep medication, or anxiolytic that would confound the assessment of tremor.
2. Trauma to the nervous system within 3 months preceding the onset of tremor.
3. History of other medical, neurological or psychiatric condition that may explain or cause tremor, including but not limited to Parkinson's disease, dystonia, cerebellar disease, family history of Fragile X syndrome, traumatic brain injury, alcohol abuse or withdrawal, benzodiazepine abuse or withdrawal, multiple sclerosis, polyneuropathy, and endocrine states such as hyperthyroidism.
4. Prior magnetic resonance-guided focused ultrasound or surgical intervention for ET such as deep brain stimulation or thalamotomy.
5. Botulinum toxin injection for ET in the 6 months prior to Screening.
6. Unwilling or unable to refrain from alcohol 24 hours before and during clinical trial visits.
7. History of substance use disorder

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/03/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/03/2022
Sample size
Target
Accrual to date
Final
24
Recruitment in Australia
Recruitment state(s)
New South WhalesQLD,VIC
Recruitment hospital [1] 0 0
Praxis Research Site - New Lambton Heights
Recruitment hospital [2] 0 0
Praxis Research Site - Southport
Recruitment hospital [3] 0 0
Praxis Research Site - Fitzroy
Recruitment hospital [4] 0 0
Praxis Research Site - Melbourne
Recruitment hospital [5] 0 0
Praxis Research Site - Parkville
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
4215 - Southport
Recruitment postcode(s) [3] 0 0
3065 - Fitzroy
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Washington
Country [3] 0 0
New Zealand
State/province [3] 0 0
Auckland
Country [4] 0 0
New Zealand
State/province [4] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Praxis Precision Medicines
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor. Part A is designed to study the dose titration from 20 to 40 mg every morning (QAM) (ie, 2 weeks with 7 days at each dose level). Part B is designed to study the dose titration from 20 to up to 120 mg QAM with at least 14 days of dosing at the highest tolerated dose for each participant. Blood levels of PRAX-944 will also be measured throughout the trial and pharmacokinetics will be evaluated.
Trial website
https://clinicaltrials.gov/study/NCT05021978
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
VP, Clinical Development
Address 0 0
Praxis Precision Medicines
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05021978